Skip to main content

Table 2 Number of events and event rates in participants after starting treatment with a GLP-1RA or a SGLT-2i and IPTW adjusted Cox regressions comparing SGLT-2i to GLP-1RA

From: Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Outcome

GLP-1RA

SGLT-2i

SGLT-2i vs. GLP-1RA

Events

Incidence rate

Events

Incidence rate

Hazard ratio, c

P-value

Total mortality

145

8.2 (6.9–9.7)

128

7.7 (6.4–9.2)

0.78 (0.61–1.01)

0.0641

MACE

348

20.4 (18.3–22.7)

392

24.4 (22.0–26.9)

1.03 (0.89–1.21)

0.6608

Fatal CVD

14

0.8 (0.4–1.3)

15

0.9 (0.5–1.5)

1.00 (0.47–2.13)

0.9947

Myocardial infarction

82

4.7 (3.7–5.8)

81

4.9 (3.9–6.1)

0.94 (0.68–1.3)

0.7295

Stroke

54

3.1 (2.3-4.0)

82

5.0 (4.0–6.2)

1.44 (0.99–2.08)

0.0562

Fatal CHF

151

8.7 (7.3–10.2)

127

7.7 (6.4–9.2)

0.83 (0.65–1.07)

0.1503

Renal composite

1864

125.2 (119.6–131.0)

1882

131.1 (125.3–137.2)

0.98 (0.92–1.05)

0.5676

30% reduction eGFR

105

6 (4.9–7.3)

87

5.3 (4.2–6.5)

0.92 (0.68–1.25)

0.5863

40% reduction eGFR

56

3.2 (2.4–4.1)

45

2.7 (2.0–3.6)

0.94 (0.62–1.43)

0.7718

Halved eGFR

40

2.3 (1.6–3.1)

28

1.7 (1.1–2.4)

0.80 (0.47–1.35)

0.4007

Macroalbuminuria

403

23.7 (21.5–26.1)

349

(21.6 (19.4–24.0)

0.89 (0.77–1.04)

0.1408

Retinopathy

9

0.5 (0.2–1.0)

18

1.1 (0.6–1.7)

2.15 (0.92–5.03

0.0784

Hypoglycemia

8

0.5 (0.2–0.9)

5

0.3 (0.1–0.7)

0.69 (0.21–2.28)

0.5392

Hyperglycemia

9

0.5 (0.2-1.0)

14

0.8 (0.5–1.4)

1.88 (0.78–4.52)

0.1571

Ketoacidosis

1

0.1 (0.0-0.3)

1

0.1 (0.0-0.3)

1.68 (1.04–2.72)

0.0346

  1. Incidence rate per 1000 patient-years with exact 95% Poisson confidence intervals. MACE, major adverse cardiovascular events. CVD, cardiovascular disease. CHF, congestive heart failure. Renal composite, any of micro- or macroalbuminuria, eGFR 50% reduction or lower than 60, dialysis, renal transplantation, renal failure, renal death. The IPTW statistical analysis is based on Cox regressions with exposure as the only covariate. The weights are defined to estimate the average treatment effect for everyone (ATE)